Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, gives an overview of the mechanism of action of anti-BCMA antibody-drug conjugates (ADCs) which are used in the treatment of multiple myeloma. ADCs have been shown to work by mediating apoptosis and phagocytosis as well as immunogenic cell death of the myeloma cells via immuno-independent and immuno-dependent means, respectively. Immunogenic cell death mediated by such agents has offered an explanation for how patients who have demonstrated discontinued treatment may still demonstrate a maintained response. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.